Abstract
Patients with rare genetic diseases (RGD) experience a lengthy diagnostic odyssey, involving complex diagnostic testing pathways. Compared to standard genetic tests, whole exome sequencing (WES) has a higher diagnostic yield and has potential to decrease time to diagnosis which is important for patients with suspected RGD and their families. We estimated time-to-diagnosis and cost-effectiveness of WES at different points in the diagnostic pathway.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
